Europe: A Future Leader in Vaccines? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Europe: A Future Leader in Vaccines?
The early part of the decade saw a decline in vaccine sales and manufacture, but finally the industry is bouncing back, with Europe particularly well placed to make an impact.


Pharmaceutical Technology Europe
Volume 22, Issue 10

In summary

Vaccines have represented an important tool in combating infectious disease and may eventually find a place in treating chronic diseases such as cancer. After a dip in activity during the early part of the decade, manufacturer interest in vaccines R&D is slowly being rekindled because of government initiatives and new public health threats. The highly organised European vaccines sector is particularly well placed to benefit from renewed market opportunities; however, it needs to tread carefully, as public concern over industry profits leaves the commercial sector open for criticism, as well as praise when it responds to new healthcare challenges.

References

1. in-Pharma Technologist, "Vaccine decline must be halted, says opinion leader" (2005). http://www.in-pharmatechnologist.com/

2. L.A. Johnson, US News and World Report, "Vaccine 'Revolution' on Horizon for AIDS, Alzheimer's, Herpes" (2009). http://www.usnews.com/

3. Synbiosis, "Rapid Assessment of Vaccine Potency" (2009). http://www.synbiosis.com/

4. The Telegraph, "Cervical cancer vaccine will cut cases by two thirds, experts calculate" (2010). http://www.telegraph.co.uk/

5. FiercePharma, "Provenge scrips hit 500 as payers agree to pay" (2010). http://www.fiercepharma.com/

6. WSJ Health Blog, "The Provenge Dilemma: Who Gets Dendreon's New Therapy?" (2010). http://blogs.wsj.com/

7. Bloomberg, "Prostate Cancer Patients Face Rationing of Provenge" (2010). http://www.businessweek.com/

8. New York Times, "Vaccine Approved for Child Infections" (2010). http://www.nytimes.com/

9. BioPharma Today, "Prevnar 13's Added Strains, Extra Studies Help Insulate Pfizer's U.S. Position" (2009). http://www.biopharmatoday.com/

10. GlaxoSmithKline, "GSK Fourth Quarter Results" (2009). http://www.gsk.com/

11. European Vaccine Manufacturers (2009). http://www.evm-vaccines.org/

12. European Vaccine Manufacturers, "Vaccines' contribution to Europe's future" (2010). http://www.evm-vaccines.org/

13. European Vaccine Manufacturers, "EVM statement to the Council of Europe hearing" (2010). http://www.evm-vaccines.org/

14. European Vaccine Manufacturers, "Human vaccines: New questions for European Vaccine Initiative" (2010). http://www.emvi.org/

15. TRASVAC. http://www.transvac.org/

16. CIDRAP, "More clouds in H1N1 vaccine supply picture" (2009). http://www.cidrap.umn.edu/

17. Novartis, "Novartis successfully demonstrates capabilities of cell-based technology for production of A(H1N1) vaccine" (2009). http://www.novartis.com/

18. WRAL.com, "World Health Organization certifies GSK's H1N1 vaccine" (2009). http://www.wral.com/

19 in-Pharma Technologist, "GSK's H1N1 orders total 440m doses" (2009). http://www.in-pharmatechnologist.com/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here